117 related articles for article (PubMed ID: 11234893)
1. Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model.
Griffin GM; Zhu T; Solonenko M; Del Piero F; Kapakin A; Busch TM; Yodh A; Polin G; Bauer T; Fraker D; Hahn SM
Clin Cancer Res; 2001 Feb; 7(2):374-81. PubMed ID: 11234893
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy in the canine prostate using motexafin lutetium.
Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells.
Renno RZ; Delori FC; Holzer RA; Gragoudas ES; Miller JW
Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3963-71. PubMed ID: 11053300
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease.
Yamaguchi A; Woodburn KW; Hayase M; Hoyt G; Robbins RC
Transplantation; 2001 Jun; 71(11):1526-32. PubMed ID: 11435960
[TBL] [Abstract][Full Text] [Related]
6. In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system.
Kostenich G; Orenstein A; Roitman L; Malik Z; Ehrenberg B
J Photochem Photobiol B; 1997 May; 39(1):36-42. PubMed ID: 9210320
[TBL] [Abstract][Full Text] [Related]
7. Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model.
Yamaguchi A; Woodburn KW; Hayase M; Robbins RC
Circulation; 2000 Nov; 102(19 Suppl 3):III275-80. PubMed ID: 11082401
[TBL] [Abstract][Full Text] [Related]
8. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates.
Solonenko M; Cheung R; Busch TM; Kachur A; Griffin GM; Vulcan T; Zhu TC; Wang HW; Hahn SM; Yodh AG
Phys Med Biol; 2002 Mar; 47(6):857-73. PubMed ID: 11936174
[TBL] [Abstract][Full Text] [Related]
9. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
Du KL; Mick R; Busch TM; Zhu TC; Finlay JC; Yu G; Yodh AG; Malkowicz SB; Smith D; Whittington R; Stripp D; Hahn SM
Lasers Surg Med; 2006 Jun; 38(5):427-34. PubMed ID: 16788929
[TBL] [Abstract][Full Text] [Related]
10. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
[TBL] [Abstract][Full Text] [Related]
11. Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma.
Lilge L; Molpus K; Hasan T; Wilson BC
Photochem Photobiol; 1998 Sep; 68(3):281-8. PubMed ID: 9747583
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
[TBL] [Abstract][Full Text] [Related]
13. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.
Sitnik TM; Henderson BW
Photochem Photobiol; 1998 Apr; 67(4):462-6. PubMed ID: 9559590
[TBL] [Abstract][Full Text] [Related]
14. Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate.
Xiao Z; Owen RJ; Liu W; Tulip J; Brown K; Woo T; Moore RB
Photodiagnosis Photodyn Ther; 2010 Jun; 7(2):106-14. PubMed ID: 20510305
[TBL] [Abstract][Full Text] [Related]
15. In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy.
Zhu TC; Hahn SM; Kapatkin AS; Dimofte A; Rodriguez CE; Vulcan TG; Glatstein E; Hsi RA
Photochem Photobiol; 2003 Jan; 77(1):81-8. PubMed ID: 12856887
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model.
Rovers JP; Saarnak AE; Molina A; Schuitmaker JJ; Sterenborg HJ; Terpstra OT
Br J Cancer; 1999 Oct; 81(4):600-8. PubMed ID: 10574244
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal photodynamic therapy in the Fischer 344 rat using 5-aminolevulinic acid and violet laser light: a toxicity study.
Major AL; Rose GS; Svaasand LO; Lüdicke F; Campana A; van Gemert MJ
J Photochem Photobiol B; 2002 Mar; 66(2):107-14. PubMed ID: 11897510
[TBL] [Abstract][Full Text] [Related]
18. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.
Dimofte A; Zhu TC; Hahn SM; Lustig RA
Lasers Surg Med; 2002; 31(5):305-12. PubMed ID: 12430147
[TBL] [Abstract][Full Text] [Related]
19. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis.
Wilson JJ; Jones H; Burock M; Smith D; Fraker DL; Metz J; Glatstein E; Hahn SM
Int J Oncol; 2004 Mar; 24(3):711-7. PubMed ID: 14767557
[TBL] [Abstract][Full Text] [Related]
20. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model.
Engbrecht BW; Menon C; Kachur AV; Hahn SM; Fraker DL
Cancer Res; 1999 Sep; 59(17):4334-42. PubMed ID: 10485481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
